Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-15 R alpha

IL-15 R alpha

Brief Information

Name:Interleukin-15 receptor subunit alpha
Target Synonym:Interleukin 15 Receptor Alpha Isoform IC2,Interleukin 15 Receptor Alpha Isoform IC8,Interleukin 15 Receptor Alpha Isoform EM2,Interleukin-15 Receptor Subunit Alpha,Interleukin 15 Receptor Alpha Isoform IC4,Interleukin 15 Receptor Alpha Isoform IC5,Interleukin 15 Receptor Alpha Isoform IC7,IL15RA,CD215,IL-15RA,IL-15 Receptor Subunit Alpha,CD215 Antigen,Interleukin 15 Receptor Subunit Alpha,Interleukin 15 Receptor Alpha Isoform IC6,Interleukin 15 Receptor, Alpha,Interleukin 15 Receptor Alpha Isofo
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ILA-HP2F6 Human PE-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (Site-specific conjugation)
ILA-HP2F6-structure
ILA-HF255 Human FITC-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified)
ILA-HF255-structure
ILA-HF255-sds
ILA-M5253 Mouse Mouse IL-15 R alpha / CD215 Protein, Fc Tag
ILA-M5253-structure
ILA-M5253-sds
ILA-H82F4 Human Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified)
ILA-H82F4-structure
ILA-H82F4-sds
ILA-H5253 Human Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified)
ILA-H5253-structure
ILA-H5253-sds

Part of Bioactivity data

ILA-H5253-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-15 R alpha, Fc Tag (Cat. No. ILA-H5253) inhibits IL-15-dependent proliferation of CTLL-2 cells. The ED50 for this effect is 2.77-4.20 ng/mL (Routinely tested).

Protocol
ILA-M5253-ELISA
Mouse IL-15 R alpha, Fc TagMouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) ELISA bioactivity

Immobilized Human IL-15, Tag Free (Cat. No. IL5-H4117) at 5 μg/mL (100 μL/well) can bind Mouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) with a linear range of 0.6-10 ng/mL (QC tested).

Protocol
ILA-HF255-MALS-HPLC
FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ) MALS images

The purity of FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) is more than 85% and the molecular weight of this protein is around 115-140 kDa verified by SEC-MALS.

Report
Bioactivity-ELISA
FITC-Labeled Human IL-15 R alpha, Fc TagFITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) ELISA bioactivity

Immobilized Human IL-15, His Tag (Cat. No. IL5-H52H8) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) with a linear range of 0.078-5 μg/mL (QC tested).

Synonym Name

IL-15 R alpha,CD215,IL15RA,IL-15RA,IL-15R-alpha

Background

IL15R is a heterotrimer of IL15RA, IL2RB and IL2RG. IL-15RA, also known as CD215, IL-15 R alpha, is a widely expressed 60 kDa transmembrane glycoprotein. High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Expression of different isoforms may alter or interfere with signal transduction. An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor. Signal transduction involves SYK. Higher levels of soluble sIL-15RA form in comparison with membrane-bound forms is present in all brain structures.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) Phase 2 Clinical Immunitybio Inc Pancreatic Neoplasms Details
SHR-1501 SHR-1501 Phase 1 Clinical Neoplasms Details
SO-C101 RLI-15; SO-C101; CYP-0150; SOT-101 Phase 1 Clinical Sotio Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Squamous Cell; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Biliary Tract Neoplasms Details
NKTR-255 NKTR-255 Phase 2 Clinical Nektar Therapeutics Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Multiple Myeloma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms Details
Recombinant human interleukin 15(Beijing Kawin) Phase 1 Clinical Beijing Kawin Technology Share-Holding Co Ltd Solid tumours Details
Inbakicept N-803; ALT-803 Phase 3 Clinical Nantkwest Inc, Altor Bioscience Corporation Multiple Myeloma; Carcinoma, Hepatocellular; Bacterial Infections; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lung Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Microsatellite Instability; Solid tumours; Chordoma; Urinary Bladder Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Hematologic Diseases; Ovarian Neoplasms Details
XmAb24306 XmAb-24306; RG-6323; RO-7310729; XmAb-306 Phase 1 Clinical Genentech Inc, Xencor Solid tumours Details
KD-033 KD-033 Phase 1 Clinical Takeda Pharma Solid tumours Details
OXS-3550 GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE; OXS-3550-TriKE Phase 2 Clinical University Of Minnesota, Oxis Biotech Myelodysplastic Syndromes; Mastocytosis, Systemic; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute Details
RTX-240 RTX-240 Phase 2 Clinical Rubius Therapeutics Leukemia, Promyelocytic, Acute Details
Heterodimeric interleukin 15(Novartis Pharma) NIZ-985 Phase 1 Clinical Novartis Pharma Ag Solid tumours; Lymphoma; Melanoma Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
QL-415 QL-415 Phase 1 Clinical Neoplasms Details
BJ-001(Boji Biomedical Technology) BJ-001 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Communicable Diseases; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap